Clinical and pathologic features (based on conventional histology and immunohistochemistry) allow breast cancer classification as hormone-receptor positive (estrogen receptor (ER) and progesterone receptor (PR)), HER2 (human epidermal growth factor receptor 2) positive, and triple negative (ER, PR, and HER2 negative). This evidence concerns the gene PGR and breast cancer.